From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

ibritumomab tiuxetan   Click here for help

GtoPdb Ligand ID: 6777

Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®
Approved drug Immunopharmacology Ligand
ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))
Compound class: Antibody
Comment: A monoclonal antibody used as a radioimmunotherapy treatment.
Immunopharmacology Disease
Disease X-Refs Comment References
non-Hodgkin lymphoma Disease Ontology: DOID:0060060
OMIM: 605027
 Approved specifically for relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma can be treated with Yttrium-90 labelled ibritumomab tiuxetan.